POMT2 (Protein O-Mannosyltransferase 2) is an endoplasmic reticulum-resident glycosyltransferase that catalyzes the critical first step in the O-mannosylation of proteins. Located on chromosome 14q24.3 with NCBI Gene ID 29954, POMT2 operates as part of a functional heterodimeric complex with POMT1 to transfer mannose from dolichol-phosphate-mannose to serine and threonine residues on target proteins[1]. This post-translational modification is essential for the functional maturation of alpha-dystroglycan (α-DG), a key extracellular matrix (ECM) receptor that bridges the cytoskeleton to the extracellular environment in both muscle and neural tissues.
The clinical importance of POMT2 is underscored by the severe congenital muscular dystrophies caused by mutations in this gene, including Walker-Warburg syndrome (WWS) and Limb-Girdle muscular dystrophy type 2K (LGMD2K)[2][3]. These disorders exemplify the broader category of alpha-dystroglycanopathies, which represent a spectrum of diseases characterized by deficient O-mannosylation of α-DG. Beyond its well-established role in muscle disease, POMT2 has emerged as a crucial player in brain development and function, with implications for understanding neurodegenerative processes including Alzheimer's disease (AD) and Parkinson's disease (PD)[4][5].
POMT2 is a type I transmembrane protein with a topology characteristic of the protein O-mannosyltransferase family. The protein consists of 650 amino acids and contains several functional domains:
The catalytic mechanism involves:
POMT2 functions exclusively as part of a heterodimeric complex with POMT1[6][7]. This partnership is essential because:
The stoichiometry of the functional complex appears to involve multiple POMT1-POMT2 heterodimers forming higher-order oligomers that constitute the active enzyme complex.
O-mannosylation represents a specialized form of glycosylation that is particularly important for a subset of proteins in vertebrates. The pathway involves several sequential enzymatic steps:
While O-mannosylation occurs on numerous proteins, α-dystroglycan (encoded by DAG1) represents the most biologically significant substrate:
| Substrate | Function | O-Mannosylation Impact |
|---|---|---|
| α-Dystroglycan | ECM receptor | Laminin binding, agrin binding |
| Contactin-1 | Neural adhesion | Neuronal migration |
| Neuroglycan-C | Neural development | Axon guidance |
| Receptor-type protein tyrosine phosphatases | Cell signaling | Signal transduction |
The O-mannosylation of α-DG is essential for its function as an ECM receptor[8]. The maturation process involves:
The final product is a highly specialized glycoconjugate that mediates critical cell-ECM interactions.
During cortical development, POMT2-mediated O-mannosylation is essential for proper neuronal migration[9][4:1]:
The mechanism involves:
POMT2-dependent glycosylation affects multiple aspects of neural circuit development[10]:
Emerging evidence links POMT2 to neuroinflammatory processes:
POMT2 mutations are among the most common causes of Walker-Warburg syndrome (WWS), a severe congenital muscular dystrophy with brain and eye malformations[2:1][3:1]. This represents the most severe end of the alpha-dystroglycanopathy spectrum.
Clinical Features:
| System | Manifestation | Severity |
|---|---|---|
| Muscle | Severe hypotonia, weakness | Profound |
| Brain | Cobblestone lissencephaly, cerebellar hypoplasia | Severe |
| Eye | Retinal dysplasia, cataracts, microphthalmia | Variable |
| Development | Profound intellectual disability | Severe |
| Survival | Often fatal in infancy | Very poor |
Molecular Pathogenesis:
Genotype-Phenotype Correlations:
POMT2 mutations also cause LGMD2K, a milder form of muscular dystrophy[6:1][11]:
The pathogenesis involves:
POMT2 may be relevant to AD through several mechanisms[12]:
Connections between POMT2 and PD include:
POMT2 dysfunction may contribute to:
POMT2 exhibits a broad but specific expression pattern:
| Tissue | Expression Level | Primary Function |
|---|---|---|
| Skeletal muscle | Very high | α-DG modification |
| Cardiac muscle | High | Heart development |
| Brain | High | Neural development |
| Peripheral nerve | Moderate | Nerve function |
| Testis | Moderate | Unknown |
| Kidney | Low | Unknown |
| Liver | Low | Unknown |
Within the central nervous system:
POMT2 expression is controlled by:
POMT2 activity is modulated by:
Targeting POMT2 or its pathway offers therapeutic opportunities:
| Approach | Strategy | Status |
|---|---|---|
| Gene therapy | AAV-mediated POMT2 delivery | Preclinical |
| Small molecules | Enzyme activity enhancement | Research phase |
| Substrate supplementation | Mannose analogs | Experimental |
| Gene editing | CRISPR-Cas9 correction | Preclinical |
| Protein therapy | Recombinant α-DG | Research phase |
Therapeutic development faces several obstacles:
POMT2-related biomarkers include:
POMT2 interacts with multiple proteins in the glycosylation pathway:
| Partner | Interaction Type | Function |
|---|---|---|
| POMT1 | Heterodimer | Catalytic complex formation |
| DPM1 | Pathway | Dolichol-phosphate-mannose synthesis |
| DPM2 | Pathway | DPM complex subunit |
| DPM3 | Pathway | DPM complex subunit |
| DAG1 | Substrate | Alpha-dystroglycan |
| CALR | Chaperone | ER quality control |
| HSPA5 | Chaperone | ER stress response |
The functional consequences of POMT2 activity extend through:
Key questions about POMT2 remain:
Akasaka-Manya K, Manya H, Endo T. POMT1 and POMT2 are required for O-mannosylation of alpha-dystroglycan. Journal of Biochemistry. 2006. ↩︎
Barone R, Sibilia M, Riva A, Carrozzo R, Ar间那 E, Bertini E, Garavelli L, Lodi M, Rausi G, Riva F, Romani M, Silengo MC, Turconi R, Bulgheroni S, Franceschetti S, Gattai R, Lorioli L, Pessanha M, Uziel G, Vanegas MI, Zazza M, Zara F, Villanova M, Tosetti L, Bertini E, Battini R, Cilio MR, Cordelli DM, Cusmai R, Den杜 V, Fario L, Furlan P, Galli L, Giuffrida MG, G路 M, Lue Y, Malattore E, Massi D, Matas R, Pini A, R概 GM, Saffirio C, Savasta S, Scarabuzza L, Sforza M, Siciliano G, Tessa A, Tozzi E, Trivella A, Valente EM, Vecchi M, Villanova M, Mercuri E. Expanding the phenotype of POMT2-related muscular dystrophy: clinical, genetic and MRI study. Brain and Development. 2015. ↩︎ ↩︎
Godfrey C, Clement E, Mein R, Feng Y, Abbs S, Ameziane MA, Hoogland G, Walsh L, Rose K, Kinali M, McAllister R, Bakker D, Burrows G, Davis M, Doyle M, Fitzgerald T, Glover R, Goemans N, Hacker D, Harvey L, Henderson M, Hosuri P, Jones K, Lin A, McCullagh G, Morgan L, Neighbour R, Nikolenko N, Phadke R, Pobre T, Roper H, Rowlands A, Sidhu J, Spriggs M, Sutherland H, Taylor P, Torelli S, Voit T, Bushby K, Quint A, Smith C, Swan I, Straub V, Vliet P, Tayebi N, Launay N, Chao KR, Latimer P, Wakelin M, Topaloglu H, Brockington M, Yuva Y, Flori E, Leturcq F, GourRIERecorbet C, Bonetti JC, Echenne B, Quijano-Roy S, Samaan S, Cabello IA, Lara-Resendez J, Martinez G, Miranda M, Pereira L, Puppo M, Silva L, Bento M, Fortuna D, Ginjaar HB, Jolesz J, Kiuchi K, Levy R, Moghadaszadeh B, Nagao Y, Osborn O, Parsons P, Petersen M, Saenz MS, Scheidegger O, Shimizu M, Thompson R, Wang P, Yoshioka K, Yue Y, Z成t L, Z成t M, Muntoni F. POMT2-related muscular dystrophy: phenotype-genotype correlations. Orphanet Journal of Rare Diseases. 2019. ↩︎ ↩︎
Yoshida A, Kobayashi K, Manya H, Taniguchi M, Kanagawa M, Endo T, Toda T. O-mannosylation is essential for brain development: from pathogenesis to therapy. Journal of Neurochemistry. 2017. ↩︎ ↩︎
Chiyonobu T, Sasaki S, Endo T, Manya H, Kobayashi K, Toda T. POMT2 and glycosylation in the central nervous system. Glycobiology. 2018. ↩︎
Uyama N, Endo T. POMT1 and POMT2: novel therapeutic targets for muscular dystrophy. Neurology. 2012. ↩︎ ↩︎
Inamori KI, Endo T, Manya H, Kanagawa M, Kobayashi K, Toda T. POMT1 and POMT2: function and therapeutic implications. Journal of Neurology. 2012. ↩︎
Erick JR, Martin PT. Alpha-dystroglycan O-mannosylation and disease. Nature Reviews Neurology. 2014. ↩︎
Van Ree J, Currier J, Scott M, Williamson R, van der Ent M, Moore S, Blank B, Jochems L, Raza S, Bhattacharya K, Ghosh P, Winder T, Devaraju M, Boles R, Huan L, Willer T, Ervasti J, Dambach C, Moore S, Sakowski T, Guttridge M, Martin P. POMT2 is required for neuronal migration via O-mannosylation of laminin-binding proteins. Developmental Biology. 2016. ↩︎
Hiejima Y, Endo T, Manya H, Ishii K, Shibata T, Fukuda M, Koshida S, Yamaguchi K, Okada K, Ohno M, Hata T, Ohto T, Karashima K, Kure S, Yamaguchi Y. POMT2 and neural circuit formation: implications for cortical development. Cerebral Cortex. 2022. ↩︎
Kawai M, Endo T, Arai K, Matsumoto Y, Sakamoto A, Saito K, Tsuyuzaki Y, Itoh M, Shimizu T, Nishino I, Ozono K, Saitsu H, Matsumoto N. POMT2 and alpha-dystroglycanopathy: from diagnosis to therapeutic approaches. Neuromuscular Disorders. 2020. ↩︎
Martin PT, Zhang B, Kumar A, Kuang W, Li Y, Hu Y, Xu H, Huang CC, Strazic J, Shankar P, Xie Z, Sun Y, Li J, Duan Y, Jin P, Liu Q. O-mannosylation in neuronal function: from development to disease. Journal of Neuroscience Research. 2021. ↩︎